Pneumococcal

Using the United States Vaccine Adverse Event Reporting System database, investigators found that pneumococcal vaccination led to predominantly nonserious adverse events.

Pneumococcal 21-valent conjugate vaccine (PCV21) was found to be immunogenic and safe in individuals living with HIV, providing significant indications of efficacy in immunocompromised patients.

A multicenter registry analysis reveals that high-risk cardiovascular patients often miss opportunities to receive pneumococcal and influenza vaccinations, showcasing gaps that could be filled by pharmacists.

Use of educational resources at a gastrointestinal office improved pneumococcal vaccine uptake in patients with celiac disease.

In STRIDE-13, the pneumococcal 21-valent conjugate vaccine (PCV21) induced robust immunogenicity in young, high-risk individuals against invasive pneumococcal disease.

The 21-valent pneumococcal conjugate vaccine (PCV21) elicited favorable immunogenicity and safety in infants and toddlers who were coadministered common pediatric vaccines, such as the measles-mumps-rubella vaccine.

Greater effectiveness was seen in children 1 year and older.

Patients with severe COVID-19 who tested positive for Streptococcus pneumoniae had higher mortality rates.

Patients in an outpatient oncology unit expressed willingness to receive a pneumococcal or influenza vaccine from a pharmacist if offered.

The implementation of nonpharmaceutical measures during the COVID-19 pandemic reduced transmission of Streptococcus pneumoniae, a key bacterium that causes pneumococcal disease.

Case highlights the importance of careful cocumentation.

In a phase 3 trial, V116 demonstrated significant immunogenicity in older adults who had not before received a pneumococcal vaccination.

Older adults in the United States continue to be burdened with disproportionate rates of community-acquired pneumonia hospitalizations, including due to serotypes covered in the recently approved V116 vaccine.

New research highlights a surge in pediatric pneumococcal pneumonia cases post COVID-19, urging a shift toward supportive treatment strategies.

Both vaccine and nonvaccine serotypes were identified as being resistant to critical antimicrobial treatments for pneumococcal disease.

Data from a retrospective study of adults in France found the highest incidence of pneumococcal disease in patients with the highest risk underlying medical conditions.

Conversely, Medicaid enrollees experienced widening gaps of pneumococcal vaccination uptake, likely driven by socioeconomic obstacles.

Education initiatives, facilitation, and immunization on the part of pharmacists were found to significantly increase uptake of pneumococcal vaccines among older adults.

Since the most recent guidelines were published, more evidence has emerged regarding intravenous corticosteroids for severely ill patients.

Patients with inflammatory rheumatic diseases may have a protective effect against serious COVID-19 outcomes once they receive a pneumococcal vaccination.

In a community of older adults, initiating a pneumococcal vaccination support program reduced annual pneumonia-related mortality by 25%, demonstrating broad public and individual health benefits.

Six months following discharge from the hospital, adults who battled community-acquired pneumonia were at heightened risk of losing the ability to perform activities and experiencing poor quality of life.

Across 3 different manufacturing lots, V116 (21-valent pneumococcal conjugate vaccine) demonstrated consistent immunogenicity and efficacy against S pneumoniae, which causes pneumococcal diseases.

Six years following vaccination with 23-valent pneumococcal polysaccharide vaccine in a Chinese population, antibody levels remained high, although not as high as 28 days following vaccination.

The expansion of pneumococcal vaccine recommendations would ultimately lead to economic and health benefits, especially for underserved populations.